The innovator will use the new capital to move into the broader diagnostics market. : Tyneside biotech startup GlycanAge has completed a $4.2m fundraise to ramp up a roll-out of its biological age test into new markets. The Newcastle business has completed the funding round which was led by venture capital firm LAUNCHub Ventures and deep-tech investors Kadmos Capital. Based in The Catalyst at the city’s science hub Newcastle Helix, GlycanAge offers a biological age test that uses glycan biomarkers to enable early prevention strategies for both consumers and healthcare professionals.